Photo: Allison Dinner/Shutterstock/Brandon Bell/Getty Images Michael Barr is no longer the Federal Reserve’s vice chair for supervision, but his regulatory mess lives on. The Trump ...

Assura rejects all-stock bid from Primary Health Properties Company considers KKR-Stonepeak offer more attractive Assura shares rise 14% Assura's shares jumped to about 46.5 pence, still just over ...

KKR and Stonepeak Partners have made a £1.61 billion ($2.08 billion; €1.92 billion) offer for UK healthcare real estate investment trust Assura. Assura, based in Altrincham, designs ...

(Reuters) -Assura said on Monday it would consider a 1.61 billion pound ($2.1 billion) offer from U.S. private equity group KKR and Stonepeak Partners, pushing shares of the British healthcare ...

Storr Group, an operational private equity firm specializing in high-growth essential services businesses, has strengthened its investment team with the addition of three key professionals in 2024: ...

Assura, the UK-listed property business that designs and invests in key NHS buildings, has received an indicative, non-binding cash offer from a consortium consisting of private equity giant Kohlberg ...

(Reuters) -Assura said on Monday it would consider a 1.61 billion pound ($2.1 billion) offer from U.S. private equity group KKR and Stonepeak Partners, pushing shares of the British healthcare real ...

Kohlberg Kravis Roberts has teamed up with fellow US investment firm Stonepeak Partners for a fifth approach worth 49.4p a share. Property and GP surgery owner Assura looks set to agree a private ...

New York-based KKR and Stonepeak Partners have put forward a 49.4 pence per share proposal valuing the real estate investment trust at £1.6billion. It includes the 0.84p per share dividend Assura ...

Assura, listed in London and owning over 600 buildings including doctors' surgeries, stated that KKR and Stonepeak Partners have proposed a potential offer worth 49.4p per share. This proposal ...

Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. No serious adverse events were tied to the British biotech’s bispecific T-cell engager in a phase 1/2 trial, and ...